Injectable Drug Delivery Articles

1. FDA Issues Final Guidance For pH Adjuster Waiver Requests For Generic Drugs 12/11/2025

   The FDA has issued a final guidance, Considerations for Waiver Requests for pH Adjusters in Generic Drug Products Intended for Parenteral, Ophthalmic, or Otic Use.

2. Is Oncology Precision Medicine Coming of Age? 12/3/2025

   Developers are releasing new data suggesting that their targeted therapy candidates may finally address some of oncology’s toughest challenges.

3. Drug Delivery Trends From 2025: Top 4 For Momentum Gains In 2026 12/2/2025

   In this article, Fran DeGrazio identifies four notable trends in drug delivery that gained momentum in 2025 and, she predicts, will continue to do so in 2026 and beyond. They are digitalization, sustainability, patient centricity, and the advanced delivery of complex biopharmaceuticals.

4. Formulation And Delivery Considerations For Cell And Gene Therapies 11/25/2025

   How can we ensure cell and gene therapies are truly transformative for patients? Success depends on the right combination of formulation, preparation, and delivery.

5. Emerging RNA Delivery Strategies For Solid Tumor Oncology 11/20/2025

   RNA shows promise in solid tumors, but delivery remains the core challenge. New targeting and delivery strategies aim to overcome tumor barriers and unlock RNA’s full therapeutic potential.

6. What Do Patients Appreciate? Therapeutic Innovation And Accessibility 11/11/2025

   At the PODD 2025 conference, patient advocates telling their own treatment stories focused on innovations in therapies and delivery methods for targeting chronic and rare diseases, leveraging technologies such as gene editing and subcutaneous delivery of complex biologics. In this article, Chief Editor Tom von Gunden carries forward the patient-centric themes of convenience and accessibility.

7. How Can We Develop New Treatments For Patients With Early Breast Cancer? 11/10/2025

   Intensity Therapeutics has developed a new approach to treating cancer — a therapy injected directly into tumors that kills cancer and stimulates a potent anticancer immune response.

8. M&A In GLP-1 Technology: Practical Recommendations And Best Practices 11/4/2025

   With explosive demand, expanding indications, and rapid innovation, the GLP-1 revolution is reshaping dealmaking. Here's a practical guide for companies negotiating M&A in this arena.

9. Drug Delivery Innovation: Getting Advanced Therapies To Patients 11/3/2025

   In this article, Fran DeGrazio recounts the evolution of drug delivery technologies as she underscores the need to innovate in the delivery of advanced therapies. Considering chronic diseases, rare diseases, and difficult-to-reach therapeutic targets, Fran offers suggestions for organizing and readying for the development and delivery of platforms, systems, and devices for next generation treatments, including personalized, precision medicines.

10. CMC For Long-Acting Injectables For TB 10/3/2025

    Long-acting injectables are a potential treatment alternative for tuberculosis, but they require key development considerations from a chemistry, manufacturing, and controls perspective.